Substance / Medication

Rimegepant

Overview

Active Ingredient
rimegepant
RxNorm CUI
2282307

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

6 trials linked to this intervention

6
Total Trials
1
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis.
Laohapiboolrattana Wattakorn, Jansem Priabprat, Anukoolwittaya Prakit et al. · J Headache Pain · 2024
PMID: 39516789Meta-AnalysisFull text (PMC)
Clinical efficacy and safety of rimegepant in the treatment of migraine: a meta-analysis of randomized controlled trials.
Wang Qinghui, Wang Shuangmei, Zhu Yi et al. · Front Neurol · 2023
PMID: 37409024Meta-AnalysisFull text (PMC)
Ubrogepant and rimegepant: systematic review, meta-analysis, and meta-regression of clinical studies.
Dong Guojun, Kjærgaard Naoko Adachi, Shakibfar Saeed et al. · Expert Opin Drug Saf · 2023
PMID: 36737057Meta-Analysis
Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis.
Johnston Karissa, Popoff Evan, Deighton Alison et al. · Expert Rev Pharmacoecon Outcomes Res · 2022
PMID: 34148501Meta-Analysis
Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings.
Polavieja Pepa, Belger Mark, Venkata Shiva Kumar et al. · J Headache Pain · 2022
PMID: 35790906Meta-AnalysisFull text (PMC)
Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials.
Gao Bixi, Yang Yanbo, Wang Zilan et al. · Front Pharmacol · 2019
PMID: 32038251Meta-AnalysisFull text (PMC)
Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double-blind, randomized controlled trial.
Kitamura Shigekazu, Matsumori Yasuhiko, Yamamoto Toshimasa et al. · Headache · 2025
PMID: 40542538RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Rimegepant (substance)
SNOMED CT
860726001
UMLS CUI
C4519126
RxNorm CUI
2282307

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
6
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.